Paris-based Sanofi S.A. announced a definitive agreement to pay $2.9 billion for diabetes drug manufacturer Provention Bio, Inc., a U.S.-based, biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes.
Provention's TzieldTM (teplizumab-mzwv) was approved in the U.S. last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D, according to the March 13 announcement.
"The acquisition is a strategic fit for Sanofi at the intersection of the company's growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes. Sanofi will continue to utilize its capabilities in diabetes to maximize TZIELD's potential as a transformative therapy globally and in the U.S., aiming to delay the onset of Stage 3 type 1 diabetes for some of the approximately 65,000 people diagnosed every year. The purchase builds on an existing co-promotion agreement with Provention Bio that is already delivering TZIELD to patients in need of this immune-mediated therapy," the announcement said.
Of the 65,000 new cases of clinical T1D diagnosed in the U.S. each year, approximately 26% are patients aged eight through 17 years. Another 35,000 are diagnosed each year in the largest five European countries.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
MoginRubin
MoginRubin
One America Plaza
600 West Broadway Suite 3300
San Diego
CA 92101
UNITED STATES
Tel: 619687 6611
E-mail: info@moginrubin.com
URL: www.moginrubin.com
© Mondaq Ltd, 2023 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing
PROVENTION BIO, INC. 
